Abstract
Serum bone Gla protein (BGP), carboxyterminal cross-linked telopeptide of type I collagen (ICTP) and aminoterminal propeptide of type III procollagen (PIIINP) levels were determined in 8 patients with autoimmune disorders (2 with systemic lupus erythematosus, 3 with rheumatoid arthritis, 2 with Sjögren’s syndrome and 1 with mixed connective tissue disease) before and after 1, 2 and 4 months of treatment with oral prednisone (at a dosage of 1 mg/kg bw/day, p.o. during the first month, then reduced to 0.1–0.2 mg/kg bw/day). Before treatment, mean serum BGP (mean±SE: 5.3±0.4 ng/ml) and ICTP (2.8±0.2 ng/ml) levels were similar to those recorded in an age and sex matched control group (n= 40: 5.4±0.1 ng/ml and 4.1±0.3 ng/ml, respectively). On the other hand, serum PIIINP levels (2.2±0.3 ng/ml) were significantly (p<0.008) lower than those found in controls (3.3±0.2 ng/ml). During glucocorticoid therapy, serum BGP levels significantly decreased after 1 month (2.9±0.4 ng/ml; p<0.001), but returned to baseline values after 2 and 4 months of treatment (4.7±0.4 ng/ml and 5.3±0.3 ng/ml, respectively). On the contrary, no significant changes were observed in serum ICTP levels during treatment (1st month: 2.7±0.4 ng/ml; 2nd month: 3.0±0.4 ng/ml; 4th month: 2.4±0.3 ng/ml). Serum PIIINP mean concentration significantly decreased after 1 (1.6±0.3 ng/ml; p<0.004) and 2 months of glucocorticoid administration (1.5±0.2 ng/ml; p<0.01); after 4 months, serum PIIINP levels were again reduced as before therapy (1.8±0.2 ng/ml). In conclusion, our study shows the presence of normal bone turnover indexes and of altered collagen synthesis in patients with autoimmune disorders. The use of high doses of oral steroids is associated with a prompt decrease of bone formation and collagen synthesis, without any significant changes in bone resorption; however, the negative effects on bone formation and collagen synthesis seem to revert after lowering corticosteroid dosage. Serial determinations of the markers of bone and collagen turnover are able to give useful and reliable information on the peripheral effects of steroids excess. 1 This work is partially supported by Progetti di Ricerca Corrente, Centro Auxologico Italiano, IRCCS, Milan, Italy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reid I.R. Pathogenesis and treatment of steroid osteoporosis. Clin. Endocrinol. (Oxf.) 30: 89, 1989.
Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112: 352, 1990.
Orth D.N., Kovacs W.J., Debold C.R. The adrenal cortex. In: Wilson J.B., Foster D.W. (Eds.), Williams Textbook of Endocrinology, ed. 8. Saunders W.B. Co, Philadelphia, 1992, p. 489.
Greenberger P.A., Hendrix R.W., Patterson R., Chmiel J.S. Bone studies in patients on prolonged systemic corticosteroid therapy for asthma. Clin. Allergy 12: 363, 1982.
Dempster D.W., Arlott M.A., Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid induced osteoporosis. Calcif. Tissue Int. 35: 410, 1983.
Reid I.R., King A.R., Alexander C.J., Ibbertson H.K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-biphosphonate (APD). Lancet 1: 143, 1988.
Cutroneo K.R., Rokowski R., Counts D.F. Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Collagen Rel. Res. 1: 557, 1981.
Sartorio A., Conti A., De Giuseppe A., Ambrosi B., Faglia G. Livelli sierici di osteocalcina e propeptide aminoterminale del procollagene III in pazienti con sindrome di Cushing prima e dopo intervento chirurgico. In: Pietri P. (Ed.), “XI Congresso Nazionale S.I.E.C. Milano, 6–9 novembre 1991”. Monduzzi Editore, 1991, p. 515.
Piovesan A., Terzolo M., Reimondo G., Pia A., Codegone A., Osella G., Boccuzzi A., Paccotti P., Angeli A. Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm. Metab. Res. 26: 234, 1994.
Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocr. Rev. 9: 437, 1988.
Price P.A., Parthemore J.C., Deftos L.J. New biochemical marker for bone metabolism. Clin. Invest. 66: 878, 1988.
Delmas P.D. Biochemical markers of bone metabolism. Presse Med. 22: 263, 1993.
Eriksen E.F., Charles P., Meisen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease. Correlation with bone histomorphometry. Bone Min. Res. 8: 127, 1993.
Sartorio A., Ambrosi B., Colombo P., Morabito F., Faglia G. Osteocalcin levels in Cushing’s disease before and after treatment. Horm. Metab. Res. 20: 70, 1988.
Sartorio A., Monzani M., Conti A., Casati G., Faglia G. Serum aminoterminal propeptide of type III procollagen (PIIINP) levels in patients with acromegaly before and after pituitary adenomectomy. Eur. J. Intern. Med. 4: 79, 1993.
Sartorio A., Conti A., Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J. 69: 846, 1993.
Gevers G., Devos P., De Roo M., Dequeker J. Increased levels of osteocalcin (bone gla protein) in rheumatoid arthritis. Br. J. Rheumatol. 28: 207, 1989.
Marhoffer W., Schatz H., Stranke H., Ulimann J., Schmidt K., Federlin K. Serum osteocalcin levels in rheumatoid arthritis: a marker of accelerated bone turnover in late onset rheumatoid arthritis. Rheumatol. 18: 1158, 1991.
Als O.S., Riis B.J., Gotfredsen A., Christiansen C., Deftos L.J. Biochemical markers of bone turnover in rheumatoid arthritis. Acta Med. Scand. 219: 209, 1986.
Kröger H., Risteli J., Risteli L, Penttilä I., Alhava E. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann. Rheum. Dis. 52: 338, 1993.
Weisman M.H., Orth R.W., Catherwood B.D., Manolagas S.C., Deftos L.J. Measures of bone loss in rheumatoid arthritis. Arch. Intern. Med. 146: 701, 1986.
Montecucco C., Baldi F., Fortina A., Tomassinin G., Caporali R., Cherie-Ligniere E.L., Fratino P. Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort. Clin. Rheumatol. 7: 366, 1988
Gennari C, Imbimbo B., Montagnani M., Bernini M., Nardi P., Avioli L.V. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif. Tissue Int. 36: 245, 1984.
Ali N.J., Capewell S., Ward M.J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 46: 160, 1991.
Sartorio A., Conti A., Ferrario S., Passini E., Re T., Ambrosi B. Serum bone Gla-protein (BGP) and carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in patients with Cushing’s syndrome before and after surgery. Postgrad. Med. J. 1996 (in press).
Oikarinen A., Autio P., Vuori J., Vaananen K., Risteli L, Kiistala U., Risteli J. Systemic glucocorticoid treatment decreases serum concentrations of carboxytelminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br. J. Dermatol. 126: 172, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Conti, A., Sartorio, A., Ferrero, S. et al. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. J Endocrinol Invest 19, 127–130 (1996). https://doi.org/10.1007/BF03349848
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349848